Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases.
Stock is 

Investor Overview

Events & Presentations

Analyst Coverage

Firm Analyst
Canaccord Genuity
John Newman Ph.D.
Cantor Fitzgerald
Alethia Young
Cowen
Marc Frahm
Goldman Sachs
Salveen Richter
H.C. Wainright
Mike King
JP Morgan
Anupam Rama
Leerink Partners
Andrew Berens M.D.
Oppenheimer & Co.
Mark Breidenbach Ph.D.
Raymond James
Danielle Brill
RBC Capital Markets
Kennen MacKay

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.